Blauvelt A, Silverberg JI, Lynde CW, et al. - This study’s findings demonstrate that the induction treatment with abrocitinib was found to be effective; most responders continuing abrocitinib did not flare. The data revealed that rescue treatment with abrocitinib plus topical therapy effectively recaptured response.

• Researchers recruited a total of 1,233 patients, 798 responders to induction (64.7%) were assigned randomly.

• The results showed that during maintenance, flare probability was 18.9%, 42.6%, and 80.9% with abrocitinib 200 mg, abrocitinib 100 mg, and placebo.

• It has been reported that after the rescue, 36.6%, 58.8%, and 81.6% of flaring patients regained IGA 0/1 response, and 55.0%, 74.5%, and 91.8% regained EASI-75 response in the abrocitinib 200 mg, abrocitinib 100 mg, and placebo groups.

• According to the findings, 63.2% and 54.0% of patients receiving abrocitinib 200 and 100 mg, respectively, experienced adverse events during maintenance.